#USA #San Diego #Stem Cell Therapy #CIRM #NueCell Bio

NueCell Bio Partners with CIRM

In an exciting development for the biotechnology sector, NueCell Bio, a pioneering translational development partner, has announced its inclusion in the California Institute for Regenerative Medicine's (CIRM) Industry Resource Partner Program. This significant milestone, formalized through a Memorandum of Understanding, aims to bolster the capabilities of researchers and companies in California as they advance their programs in stem cell and gene therapies from the initial stages of discovery to clinical development.

Since its establishment by California voters in 2004, CIRM has been at the forefront of accelerating innovations in stem cell and gene therapy, particularly for those with unmet medical needs. Over the years, CIRM has successfully directed an impressive $8.5 billion towards supporting groundbreaking research, funding over 1,400 projects, and generating more than $38 billion in follow-on investments. This collaborative effort has not only enhanced the state's biotechnology landscape but also expanded access to transformative medical treatments.

NueCell Bio stands ready to augment the resources available to CIRM-funded programs, particularly at the pivotal translational stage. With its extensive expertise in bioprocessing, NueCell Bio is poised to play a crucial role in bridging the gap between laboratory research and Good Manufacturing Practice (GMP) readiness. The firm operates from a state-of-the-art facility in Sorrento Valley, covering more than 26,300 square feet, where it supports diverse cell therapy initiatives including autologous and allogeneic programs utilizing both unmodified cells and genetically modified variants, such as CAR-T, NK, and various stem cell therapies.

Michael Wourms, CEO of NueCell Bio, expressed enthusiasm about this partnership, highlighting the critical nature of the decisions made during the early stages of development. He noted, “The question that decides a program’s future is no longer just who manufactures it. It’s whether it can get to manufacturing at all.” His statement underscores the importance of quality scientific decisions made well in advance of GMP.

Through its proprietary platform, NueStack™, NueCell Bio integrates advanced technology from iPSC development and gene editing to comprehensive analytics and manufacturing readiness, ensuring that each program is tailored to its unique needs rather than adhering to a rigid sequence. This strategic approach not only enhances manufacturability but also ensures that critical biological characteristics are preserved throughout the process.

The firm’s services encompass a broad range of functionalities, from cell line selection and characterization to cell banking and regulatory compliance, continuously aligning their methodologies with emerging industry standards. As programs evolve from two-dimensional to three-dimensional cell cultures and scale in bioreactors, NueCell Bio guarantees that the lineage requirements are meticulously captured and maintained, promoting consistent manufacturing practices.

NueCell Bio's collaboration with CIRM marks a significant advance for the collective mission of enhancing the accessibility of innovative therapies in California and beyond. By aligning its efforts with CIRM's considerable resources and funding, NueCell Bio is well-positioned to support the development of complex cell therapy programs, including those derived from induced pluripotent stem cells and other advanced methodologies.

With a strong foothold in the regenerative medicine community, NueCell Bio's engagement in this partnership is a clear indication of its commitment to advancing therapeutic solutions that will not only benefit patients in California but can also set a precedent for global health advancements. As the landscape of regenerative medicine continues to evolve, this collaboration will be crucial in navigating the complexities involved in clinical development and ensuring that innovative solutions are brought to fruition.